Skip to main content
Premium Trial:

Request an Annual Quote

Chiron Acquires Sagres Discovery

NEW YORK, July 6 (GenomeWeb News) - Chiron has acquired oncogenomics firm Sagres Discovery, the companies said today.

 

Sagres Discovery, of Davis, Calif., has been using high-throughput genomic technologies to analyze mouse models of cancer. Based on the results, the company has assembled a set of oncology targets it calls the Oncogenome.

 

"With the wealth of targets from Sagres, we expect to be able to maximize the value of our collaboration with Xoma and our small molecule drug discovery program for the development and commercialization of new drugs for the treatment of cancer," commented Kenneth Bair, senior vice president and head of research at Chiron BioPharmaceuticals, in a statement.

 

Sagres had several collaborations, including with the Genome Institute of Singapore and Boehringer Ingelheim, both announced last year.

 

Neither company disclosed financial terms of the acquisition.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.